Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Disparities Progress Report and what oncologists can do to combat them.
Commentary|Podcasts|August 7, 2026
Supplements and Featured Publications
- Integrating Liquid Oncolytics Into Cancer Care
- Volume 1
- Issue 1
Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD
Fact checked by: Riley Kandel, Ashling Wahner
Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.
Welcome to OncLive On Air®! I’m your host today, Riley Kandel.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we spoke with Jonathan Trent, MD, PhD, a professor in the Department of Medicine in the Division of Medical Oncology, associate director of Clinical Research, and the director of the Sarcoma Medical Research Program at the University of Miami Miller School of Medicine in Florida.
In our exclusive interview, Dr Trent discussed currently approved TKIs for patients with gastrointestinal stromal tumor (GIST), including imatinib (Gleevec), sunitinib (Sutent), regorafenib (Stivarga), and ripretinib (Qinlock). Trent dove into how these TKIs have improved outcomes for patients and touched on common adverse effects seen with these therapies, as well as how to manage these toxicities and maintain treatment adherence among patients. He also looked to liquid formulations of TKIs that are in development and the benefits they would bring to GIST management.
_____
That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
Articles in this issue
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.
Olomorasib earned breakthrough therapy status as a monotherapy for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Trending on OncLive
1
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
2
FDA Flashback: Breast Cancer Decisions and News From July 2026
3
Dr Wong on the FDA Approval of Vusolimogene Oderparepvec-wtpg Plus Nivolumab in Melanoma
4
Dr Brufsky on the FDA Approval of Gedatolisib Plus Fulvestrant ± Palbociclib in PIK3CA Wild-Type Breast Cancer
5